Protara Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 10.22 million compared to USD 38.97 million a year ago. Basic loss per share from continuing operations was USD 0.9 compared to USD 3.46 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.925 USD | -4.10% | +10.80% | +55.99% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.99% | 33.44M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- TARA Stock
- News Protara Therapeutics, Inc.
- Protara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023